MetaVia Inc. (MTVA) stock
MTVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.30+0.00 (0.00%)
Close on Nov 13, 2026Market cap $8.56MP/E –Yield –
MetaVia r&d expenses
Research and development expenses are spending on new products and technology.
MetaVia's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.41M, down 20.8% year over year. For fiscal 2025 it was $6.80M, down 68.4% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is $22.69M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.80M | -68.4% |
| FY2024 | Dec 31, 2024 | $21.55M | +135.3% |
| FY2023 | Dec 31, 2023 | $9.16M | +229.7% |
| FY2022 | Dec 31, 2022 | $2.78M | -57.6% |
| FY2021 | Dec 31, 2021 | $6.55M | +44.5% |
| FY2020 | Dec 31, 2020 | $4.53M | -14.9% |
| FY2019 | Dec 31, 2019 | $5.32M | +5.1% |
| FY2018 | Dec 31, 2018 | $5.07M | -77.7% |
| FY2017 | Dec 31, 2017 | $22.69M | +159.6% |
| FY2016 | Dec 31, 2016 | $8.74M | +119.0% |
| FY2015 | Dec 31, 2015 | $3.99M | +7575.0% |
| FY2014 | Dec 31, 2014 | $52.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.59M | +35.3% |
| Q2 FY2026 | Jun 30, 2026 | $3.48M | +49.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.10M | -9.7% |
| Q4 FY2025 | Dec 31, 2025 | $241.00K | -94.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.91M | -57.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.32M | -71.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.33M | -52.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.06M | +5.0% |
| Q3 FY2024 | Sep 30, 2024 | $4.52M | +97.1% |
| Q2 FY2024 | Jun 30, 2024 | $8.07M | +241.5% |
| Q1 FY2024 | Mar 31, 2024 | $4.90M | +669.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.87M | +1167.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.29M | +301.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.36M | +140.7% |
| Q1 FY2023 | Mar 31, 2023 | $637.00K | -30.8% |
| Q4 FY2022 | Dec 31, 2022 | $305.00K | -84.7% |
| Q3 FY2022 | Sep 30, 2022 | $571.00K | -59.0% |
| Q2 FY2022 | Jun 30, 2022 | $982.00K | -51.2% |
| Q1 FY2022 | Mar 31, 2022 | $920.00K | -19.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.00M | +353.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.39M | +10.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.01M | +198.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.14M | -46.9% |
| Q4 FY2020 | Dec 31, 2020 | $440.00K | -69.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.27M | +10.0% |
| Q2 FY2020 | Jun 30, 2020 | $674.00K | -28.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.15M | +19.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.43M | -22.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.15M | -67.5% |
| Q2 FY2019 | Jun 30, 2019 | $948.00K | -76.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.80M | -63.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.83M | -63.9% |
| Q3 FY2018 | Sep 30, 2018 | $3.54M | -45.4% |
| Q2 FY2018 | Jun 30, 2018 | $3.96M | -32.2% |
| Q1 FY2018 | Mar 31, 2018 | $4.98M | -5.7% |
| Q4 FY2017 | Dec 31, 2017 | $5.08M | +5.0% |
| Q3 FY2017 | Sep 30, 2017 | $6.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.84M | – |
See a number that looks wrong?